The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
We develop natural psilocybin products,
medicinal formulations and treatment protocols
to treat mental health disorders in a clinical environment.
Learn More
With experience in building disruptive brands and creating
routes to market, we are focused on the development
of over-the-counter proprietary nutraceutical products.
Learn More
We operate one of the first federally licensed commercial
psilocybin cultivation and production facilities in the world.
Learn MoreBringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Our News
Psyence Group Corporate Update
Psyence Group Corporate Update
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements [...]
Our Global Footprint
Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.